Transurethral robotic en-bloc TURBT-challenging status quo. Presented of the John K. Lattimer Lecture by @jteoh_hk@CUHKMedicine. #AUA26 written coverage by Kantapon Tangwiwat, MD @UCIrvine on UroToday > https://t.co/Kr3Xg8fW7b @AmerUrological#AUA2026
🚨 Se acabó el comunismo en Polonia.
Polonia ha ilegalizado el Partido Comunista tras una decisión del Tribunal Constitucional, que considera que su ideología vulnera la Constitución al basarse en principios totalitarios.
📲 Lee la noticia al completo: https://t.co/yuvjgB7sz6
Nightmares of RIRS. Respiratory movement is risky and cause significant bleeding. Procedure aborted and fortunately it went well no significant hematuria, hematoma or late vascular complication. General anesthesia with controlled apnea is very helpful to avoid such nightmare
#EMBARK trial reports overall survival benefit for enzalutamide with ADT in high-risk non-metastatic #ProstateCancer. @SFreedlandMD@CedarsSinai joins @zklaassen_md@GACancerCenter to discuss on UroToday. The conversation highlights that combination therapy benefits all patient subsets and represents a new standard of care, with shared decision-making determining optimal treatment for individual patients. #WatchNow > https://t.co/9CXUQTPJuX
🧬 Why Docetaxel Works in Prostate Cancer (and Others Don’t 😮)
Not all taxanes are born equal — one cracked the prostate code 🧩
💥 Docetaxel = The AR Disruptor
•Freezes microtubules → mitotic chaos (G₂/M arrest)
•Phosphorylates Bcl-2 → flips the “self-destruct” switch
🚫 Stops androgen receptor (AR) from entering the nucleus — and that’s its secret weapon!
⚖️ Paclitaxel vs Cabazitaxel: Why They Miss the Mark?
•Paclitaxel → can’t penetrate prostate tumor microenvironment effectively ❌
•Cabazitaxel → beats resistance pumps 💪 but doesn’t block AR trafficking as powerfully
👉 Only docetaxel truly starves the tumor of AR signaling
🧠 Proof in Trials
•mCRPC: OS ↑ in TAX-327
•mHSPC: OS ↑ in CHAARTED & STAMPEDE
•Now the backbone for ARSI + PARPi combos
💡 Takeaway:
Docetaxel isn’t just chemo - it’s a molecular double agent that shuts down both cell division and androgen signaling.
🔖 Save this gem for viva, boards & clinic rounds!
#OncoTwitter #ProstateCancer #MedTwitter @myESMO@esmo_open@OncoAlert@ASCO@Uromigos
@Muni_LasCondes cuando el pelotuo de inspector de tránsito pasa partes por mal estacionados y su auto lo deja encima de la vereda y en zona de no estacionar por salida de camiones. Educando con el ejemplo.
Inspector: Fabián Araya Salcedo
Patente: TLDD40
This study shows PSMA PET/CT outperforms traditional imaging and nomograms in staging intermediate-risk prostate cancer—accurately identifying patients who can safely avoid pelvic lymph node dissection. #TheVoiceofUrology#AUA
Click to read the article: https://t.co/RcghaWmHXQ
The Magical World of AEEP, with key insights, tips and tricks as provided by @BristolWhiles. Part of a fantastic educational course on Overcoming Challenging Scenarios for the Novice Enucleator!
@Urology_KU@young_endosoc#WCET25
Metastasis-directed therapy improves outcomes in oligometastatic #ProstateCancer in #WOLVERINE study. @ChadTangMD@MDAndersonNews sits down with @l_ballas@CedarsSinai to discuss a meta-analysis of STOMP, ORIOLE, ARTO, EXTEND & COMET-SABR trials on oligometastatic #ProstateCancer. #WatchNow > https://t.co/r4QtQ0p9yz
BN152: Amazing! THE STONE SENSE by IPG Medical. First time presented at AUA-2025-Don’t miss it:MONDAY 28th-1.00pm(Room505)«MP29-15: Pre-clinical Evaluation of Laser System with EmissionControl based on Stone vs Tissue Recognition».The first AI tool for Endourology&max.LaserSafety
42yo, no surgical history, 57mm bladder stone. Endoscopic lithotripsy with @UCencomex 100w cyber ho holmium laser. In the center of the stone, a lost copper IUD.